FRM
BMRN icon

Fore Research & Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Fore Research & Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-187,800
Closed -$12.8M – 72
2014
Q1 		$12.8M Buy
187,800
+87,800
+88% +$6.47M 0.42% 42
2013
Q4 		$7.04M Buy
+100,000
New +$6.79M 0.27% 34

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fore Research & Management's BMRN Position: Q2 2015 in Review

Fore Research & Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2015, closing a stake of 10,000 shares — an estimated $1.25M sold.

Fore Research & Management first reported a position in BMRN in Q1 2014 and held it in 5 quarters. The position peaked at $3.61M in Q3 2014. 391 funds tracked by Wall St. Rank hold BMRN as of Q2 2015.

  • Fore Research & Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Fore Research & Management sold 10,000 BioMarin Pharmaceuticals shares in Q2 2015, an estimated $1.25M.
  • Fore Research & Management first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 5 quarters.
  • Fore Research & Management's BioMarin Pharmaceuticals position peaked at $3.61M in Q3 2014.
  • 391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2015.

Based on Fore Research & Management's 13F filing for Q2 2015, filed 14 Aug 2015.